Our novel therapeutic prostate cancer vaccine has been developed by use of GM-CSF/TNFα surface-modified PC-3 cells to treat the patients with advanced prostate cancer [5], and thus large-scale production of anchorage-dependent PC-3 prostate cancer cells will be required for vaccine manufacturing. The gene discussed is CSF2; the disease is Familial prostate cancer.